The Future of Hypercortisolism Care in Cardiology

In this episode, ‘The Future of Hypercortisolism Care in Cardiology,’ the panelists explore how increasing awareness of hypercortisolism may reshape cardiovascular practice, education, and multidisciplinary care models. As emerging evidence continues to highlight the prevalence of hypercortisolism among patients with resistant hypertension and other cardiometabolic conditions, the expert faculty discuss how advances in screening and treatment could drive broader recognition of this underdiagnosed condition.

The panel draws parallels between hypercortisolism and other diseases that were once considered rare, including cardiac amyloidosis, hypertrophic cardiomyopathy, and pulmonary hypertension. They examine how the availability of effective therapies transformed awareness, screening practices, and the development of specialized clinical programs in those fields, and consider whether a similar evolution may occur for hypercortisolism. The discussion highlights the potential role of cardiometabolic clinics and multidisciplinary collaborations involving cardiology, endocrinology, nephrology, and primary care in improving identification and management of patients with cortisol-related hypertension.

The faculty also reflect on the growing role of cardiologists in managing complex cardiometabolic diseases. Drawing comparisons to the widespread adoption of SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular care, they discuss how clinician comfort with new therapies can evolve as evidence accumulates and treatment options expand. In addition, the panel emphasizes the importance of education and training for future healthcare professionals, particularly regarding secondary causes of hypertension and the need for earlier evaluation of endocrine contributors to cardiovascular disease. The panel of experts discusses how improved screening, expanding therapeutic options, and collaborative care models may help optimize outcomes for patients with hypercortisolism and resistant hypertension.

The next episode in this series, ‘Hypercortisolism Recognition and Action in Resistant Hypertension,’ features the panelists discussing key clinical takeaways from emerging evidence linking hypercortisolism to resistant hypertension and cardiometabolic disease. They highlight the importance of screening, early recognition, and referral strategies that may help improve outcomes and reduce treatment burden for affected patients.